TEVIMBRA
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA is pd-1 ligands pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for metastatic esophageal squamous cell carcinoma (escc) after prior systemic chemotherapy. First approved in 2025.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA (tislelizumab-jsgr) is a PD-1 inhibitor monoclonal antibody approved for metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. It works by binding to PD-1 on T cells and blocking interaction with PD-L1 and PD-L2, thereby releasing immune checkpoint inhibition and restoring anti-tumor immune response. The mechanism has demonstrated efficacy in preclinical xenograft and transgenic mouse models.
Growth
Early-stage growth phase with moderate competitive pressure (30) suggests opportunity for brand building and market expansion within the ESCC oncology franchise.
Mechanism of Action
PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.